Skip to content
Gdańsk Bay Tech Innovation ecosystem calendar · Pomerania
/
← All events

Nabór UE: Biotechnology for Healthy Ageing

You can gain funding for breakthrough biotechnology slowing down aging and build a network of contacts among longevity industry leaders. This is a chance for your idea of an intervention based on molecular phenotyping to pass from horse level

When Wednesday, 28 October 2026
Time 01:00
City online

Expected impact:

This challenge aims to accelerate the development and absorption of clinically validated interventions, which are the cause of many age-related diseases. It will:

  • Providing biotechnological interventions for healthy ageing
  • Accelerating the implementation of individualized ageing care based on phenotypic molecular
  • Make recommendations on the regulatory pathways for ageing as a means of informing developers, regulators and other decision-makers; and
  • Improving literacy on the life expectancy of citizens.

Expected result:

The ambitious proposals presented in this call will:

  • Proof-of-concepts (TRL3 completed) from biotechnology or intervention drugs that prevent or delay the onset or return of age-related disease in the vertebrate model system, based on the characteristics of ageing, taking into account the practical challenges associated with the implementation of such intervention
  • tools to facilitate the development or adoption of these interventions, such as confirmation of the verification of biomarkers’ signature concepts or appropriate preclinical models, and
  • An approach to addressing common regulatory obstacles and societal challenges linked to age-related interventions to facilitate their adoption.

Portfolio approach

The portfolio of projects selected under this challenge will ensure that projects developing interventions, biomarkers and NAM are covered, taking into account the following portfolio composition guidelines:

  • Interventions: no more than 5 projects. The portfolio of selected projects should jointly address various molecular and cellular processes related to ageing and various age-related diseases.
  • Biomarkers: no more than 3 projects. Projects will be selected to intercept different applications a
Content processed by AI. The description was machine-translated from the original language, the English version was produced by machine translation, the “why attend” blurb was written by an AI model. The organiser's page is authoritative. View the original from the organiser →
Show original description

Expected Impact: This Challenge looks to accelerate the development and uptake of clinically validated interventions that target the root cause of multiple age-related morbidities. It will: • Deliver biotechnology-based interventions for healthy ageing • Accelerate the implementation of personalised care in ageing based on molecular phenotyping​ • Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers​, and • Improve citizen literacy on longevity. Expected Outcome: Ambitious proposals put forward under this call will deliver: • Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention • Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models​, and • Approaches to address the shared regulatory hurdles and societal challenges linked to ageing-related interventions, thereby facilitating their adoption​. Portfolio approach The portfolio of projects selected under this Challenge will ensure a coverage of projects developing interventions, biomarkers and NAMs, considering the following guidelines for portfolio composition: • Interventions: no more than 5 projects. The portfolio of selected projects should collectively address a variety molecular and cellular processes related to ageing, and a variety of different age-related diseases. • Biomarkers: no more than 3 projects. Projects will be selected to capture different application areas (diagnostic, predictive, prognostic biomarker), with preference to the inclusion of at least one diagnostic biomarker). • NAMs: No more than 2 projects. Projects will be selected to capture a…